gms | German Medical Science

21. Jahrestagung der Retinologischen Gesellschaft gemeinsam mit dem
8. Symposium der International Society of Ocular Trauma

Deutsche Gesellschaft für Retinologie
International Society of Ocular Trauma

19.06. - 22.06.2008, Würzburg

Bevacizumab versus triamcinolone for treatment of diabetic macular edema in a pair-matched analysis

Meeting Abstract

  • Rainer Guthoff - Würzburg/Germany
  • K. Hennemann - Würzburg/Germany
  • W. Goebel - Würzburg/Germany
  • W.F. Schrader - Würzburg/Germany

Retinologische Gesellschaft. International Society of Ocular Trauma. 21. Jahrestagung der Retinologischen Gesellschaft gemeinsam mit dem 8. Symposium der International Society of Ocular Trauma. Würzburg, 19.-22.06.2008. Düsseldorf: German Medical Science GMS Publishing House; 2008. DocISOTRG2008V140

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/rg2008/08rg140.shtml

Veröffentlicht: 18. Juni 2008

© 2008 Guthoff et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: To retrospectively analyze the outcome of patients with diabetic macular edema (ME) treated by bevacizumab vs. triamcinolone.

Methods: 14 patients treated with bevacizumab for argon laser-refractory diabetic ME were matched pairwise with 5 TA treated patients in regard to initially comparable VA and central retinal thickness (CRT). VA and CRT, measured by OCT, at first and last presentation were evaluated. Previously vitrectomized eyes were not included.

Results: In the BVO group, mean initial VA (LogMAR) of bevacizumab patients (mean age 70±13 years) and TA patients (mean age 65±9 years) was 0.2±0.1 and 0.19±0.09, respectively. Initial CRT of bevacizumab patients and TA patients was 470±181 µm and 469±169 µm, respectively. Final VA of bevacizumab patients after 1.3 injection was 0.17±0.05, mean 0,2, at the end of a mean follow up of 8±3.8 months. Final VA of TA patients after a mean of 1.1 injections was 0.21±0.1, median 0,2, at the end of a mean follow up of 9.5±5.3 months. CRT decreased by 119±212µm, median 92µm, after bevacizumab und by 103±171µm, median 92µm, after TA.

Conclusions: This pair-machted analysis showed no significant long-term effect of both bevacizumab and TA on chronic diabetic macular edema after a single up to 3 injections.